Clinuvel Pharmaceuticals (CUVL) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Surrozen (SRZN) has outperformed Clinuvel Pharmaceuticals (CUVL) over the past year, gaining 99.2% versus a loss of 31.6%. Over five years, SRZN leads with a -70.5% price change compared with -81.6% for CUVL. Surrozen is the larger company by market cap ($352.5 million vs $282.7 million), about 1.2 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Surrozen does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUVL | SRZN |
|---|---|---|
| Share price | $5.60 | $29.99 |
| Market cap | $282.73M | $352.49M |
| 1-day change | 0.00% | +7.22% |
| YTD return | -33.96% | +23.76% |
| 1-year return | -31.62% | +99.22% |
| 5-year return | -81.60% | -70.50% |
| P/E ratio (TTM) | 12.44 | — |
| EPS (TTM) | $0.45 | $-39.08 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $0.05 | $0.00 |
| 52-week high | $8.92 | $37.83 |
| 52-week low | $5.53 | $11.39 |
| Distance from 52-week high | -37.22% | -20.72% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +61.39% |
| Average volume | 13.01K | 483.28K |
| Shares outstanding | 50.49M | 11.75M |
| Employees | — | 44 |
| Sector | Miscellaneous | Health Care |
| Industry | Miscellaneous | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed CUVL by 130.8 percentage points over the past year.
- The two companies sit in different sectors: Clinuvel Pharmaceuticals in Miscellaneous and Surrozen in Health Care.
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
CUVL vs SRZN FAQ
Which is bigger, Clinuvel Pharmaceuticals or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $352.49M compared with $282.73M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, CUVL or SRZN?
SRZN returned +99.22% over the past 12 months, compared with -31.62% for CUVL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Clinuvel Pharmaceuticals or Surrozen?
Clinuvel Pharmaceuticals pays a dividend yielding 0.89%, while Surrozen does not currently pay a regular dividend.
Are Clinuvel Pharmaceuticals and Surrozen in the same industry?
No. Clinuvel Pharmaceuticals is in the Miscellaneous sector, while Surrozen is in Health Care.